Postępy w Kardiologii Interwencyjnej

Non-invasive methods of risk assessment in patients with chronic coronary syndrome: which patients will experience an acute event?

Kacper J. Pająk 1
,
Kamil Tkacz 1
,
Natalia Kaleta 1
,
Julia Krawczyk 1
,
Aleksandra Gąsecka 1

  1. 1st Department of Cardiology, Medical University of Warsaw, Poland

Adv Interv Cardiol

DOI: https://doi.org/10.5114/aic.2026.164776
Data publikacji online: 2026/09/15
Article file
Non-invasive methods.pdf
  1. Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet 2021; 397: 1085-94.
  2. Boden WE, Marzilli M, Crea F, et al. Evolving management paradigm for stable ischemic heart disease patients. JACC 2023; 81: 505-14.
  3. Samuels BA, Shah SM, Widmer RJ, et al. Comprehensive management of ANOCA, Part 1-definition, patient population, and diagnosis: JACC state-of-the-art review. J Am Coll Cardiol 2023; 82: 1245-63.
  4. Östlund-Papadogeorgos N, Ekenbäck C, Jokhaji F, et al. Blood haemoglobin, renal insufficiency, fractional flow reserve and plasma NT-proBNP is associated with index of microcirculatory resistance in chronic coronary syndrome. Int J Cardiol 2020; 317: 1-6.
  5. De Bacquer D, Ueda P, Reiner Ž, et al. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. Eur J Prev Cardiol 2022; 29: 328-39.
  6. Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA 2022; 327: 662-75.
  7. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). European Heart J 2024; 45: 3415-537.
  8. Zhou J, Li C, Cong H, et al. Comparison of different investigation strategies to defer cardiac testing in patients with stable chest pain. JACC Cardiovasc Imaging 2022; 15: 91-104.
  9. Winther S, Schmidt SE, Foldyna B, et al. Coronary calcium scoring improves risk prediction in patients with suspected obstructive coronary artery disease. J Am Coll Cardiol 2022; 80: 1965-77.
  10. Brix GS, Rasmussen LD, Rohde PD, et al. Calcium scoring improves clinical management in patients with low clinical likelihood of coronary artery disease. JACC Cardiovasc Imaging 2024; 17: 625-39.
  11. Zhou J, Zhao J, Li Z, et al. Coronary calcification improves the estimation for clinical likelihood of obstructive coronary artery disease and avoids unnecessary testing in patients with borderline pretest probability. Eur J Prev Cardiol 2022; 29: e105-7.
  12. Rasmussen LD, Schmidt SE, Knuuti J, et al. Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials. Eur Heart J 2025; 46: 473-83.
  13. Chen T, Shao D, Zhao J, et al. Comparison of the RF-CL and CACS-CL models to estimate the pretest probability of obstructive coronary artery disease and predict prognosis in patients with stable chest pain and diabetes mellitus. Front Cardiovasc Med 2024; 11: 1368743.
  14. Tan Y, Liu C, Chen T, et al. Coronary artery calcium score-weighted clinical likelihood model performance in patients with stable chest pain and coronary artery calcium scores of zero. Rev Cardiovasc Med 2024; 25: 85.
  15. Rasmussen LD, Schmidt SE, Knuuti J, et al. Exercise electrocardiography for pre-test assessment of the likelihood of coronary artery disease. Heart 2024; 110: 263-70.
  16. Napoli G, Mushtaq S, Basile P, et al. Beyond stress ischemia: unveiling the multifaceted nature of coronary vulnerable plaques using cardiac computed tomography. J Clin Med 2024; 13: 4277.
  17. Golub Ilana S, Termeie Orly G, Kristo S, et al. Major global coronary artery calcium guidelines. JACC Cardiovasc Imaging 2023; 16: 98-117.
  18. Lo-Kioeng-Shioe MS, Rijlaarsdam-Hermsen D, van Domburg RT, et al. Prognostic value of coronary artery calcium score in symptomatic individuals: a meta-analysis of 34,000 subjects. Int J Cardiol 2020; 299: 56-62.
  19. Biavati F, Saba L, Boussoussou M, et al. Coronary artery calcium score predicts major adverse cardiovascular events in stable chest pain. Radiology 2024; 310: e231557.
  20. Razavi AC, Whelton SP, Blumenthal RS, et al. Beyond the Agatston calcium score: role of calcium density and other calcified plaque markers for cardiovascular disease prediction. Curr Opin Cardiol 2025; 40: 56-62.
  21. Yong Y, Giovannucci J, Pang SN, et al. Coronary artery calcium density and risk of cardiovascular events: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2025; 18: 294-304.
  22. Soroosh GP, Tasdighi E, Adhikari R, Blaha MJ. Coronary artery calcium in 2023: guidelines for LDL-C goals, non-statin therapies, and aspirin use. Prog Cardiovasc Dis 2024; 84: 2-6.
  23. Mortensen MB, Gaur S, Frimmer A, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. JAMA Cardiol 2022; 7: 36-44.
  24. Gaba P, Gersh BJ, Muller J, et al. Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research. Nat Rev Cardiol 2023; 20: 181-96.
  25. Dawson LP, Layland J. High-risk coronary plaque features: a narrative review. Cardiol Ther 2022; 11: 319-35.
  26. Williams MC, Kwiecinski J, Doris M, et al. Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction. Circulation 2020; 141: 1452-62.
  27. Gallone G, Bellettini M, Gatti M, et al. Coronary plaque characteristics associated with major adverse cardiovascular events in atherosclerotic patients and lesions: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2023; 16: 1584-604.
  28. Nurmohamed NS, Min JK, Anthopolos R, et al. Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. European Heart J 2024; 45: 3735-47.
  29. Bell JS, Weir-McCall J, Nicol E, et al. Plaque quantification from coronary computed tomography angiography in predicting cardiovascular events: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr 2025; 19: 423-32.
  30. Dahdal J, Jukema RA, Maaniitty T, et al. CCTA-Derived coronary plaque burden offers enhanced prognostic value over CAC scoring in suspected CAD patients. Eur Heart J Cardiovasc Imaging 2025; 26: 945-54.
  31. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606.
  32. Walpot J, Van Herck P, Van de Heyning CM, et al. Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events (MACE) and mortality in patients with heart disease and critically ill patients. Part I: Epicardial adipose tissue. Anaesthesiol Intensive Ther 2023; 55: 141-57.
  33. West HW, Siddique M, Williams MC, et al. Deep-learning for epicardial adipose tissue assessment with computed tomography: implications for cardiovascular risk prediction. JACC Cardiovasc Imaging 2023; 16: 800-16.
  34. Nogajski Ł, Mazuruk M, Kacperska M, et al. Epicardial fat density obtained with computed tomography imaging – more important than volume? Cardiovasc Diabetol 2024; 23: 389.
  35. Němečková E, Krása K, Malý M. The perivascular fat attenuation index: bridging inflammation and cardiovascular disease risk. J Clin Med 2025; 14: 4753.
  36. Hara T, Sata M. Roles of perivascular adipose tissue in the pathogenesis of atherosclerosis – an update on recent findings. Front Physiol 2024; 15: 1522471.
  37. Tanaka K, Sata M. Roles of perivascular adipose tissue in the pathogenesis of atherosclerosis. Front Physiol 2018; 9: 3.
  38. Konwerski M, Gromadka A, Arendarczyk A, et al. Atherosclerosis pathways are activated in pericoronary adipose tissue of patients with coronary artery disease. J Inflamm Res 2021; 14: 5419-31.
  39. Wang LL, Xiong YB, Feng XY, et al. Computed tomography-based assessment of pericoronary adipose tissue in cardiovascular diseases: diagnostic and prognostic implications. World J Radiol 2025; 17: 107281.
  40. Oikonomou EK, Marwan M, Desai MY, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 2018; 392: 929-39.
  41. Tan N, Marwick TH, Dey D, et al. Association of pericoronary adipose attenuation with major adverse cardiovascular events and high-risk plaque. JACC Cardiovasc Imaging 2025; 18: 884-94.
  42. Zhang R, Ju Z, Li Y, et al. Pericoronary fat attenuation index is associated with plaque parameters and stenosis severity in patients with acute coronary syndrome: a cross-sectional study. J Thorac Dis 2022; 14: 4865-76.
  43. Giesen A, Mouselimis D, Weichsel L, et al. Pericoronary adipose tissue attenuation is associated with non-calcified plaque burden in patients with chronic coronary syndromes. J Cardiovasc Comput Tomogr 2023; 17: 384-92.
  44. Rajiah P, Cummings KW, Williamson E, Young PM. CT fractional flow reserve: a practical guide to application, interpretation, and problem solving. Radiographics 2022; 42: 340-58.
  45. Mittal Tarun K, Hothi Sandeep S, Venugopal V, et al. The use and efficacy of FFR-CT. JACC Cardiovasc Imaging 2023; 16: 1056-65.
  46. Jin X, Jin X, Wu X, et al. Distribution of FFRCT in single obstructive coronary stenosis and predictors for major adverse cardiac events: a propensity score matching study. BMC Med Imaging 2022; 22: 59.
  47. Nørgaard BL, Gaur S, Fairbairn TA, et al. Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis. Heart 2022; 108: 194-202.
  48. Wada S, Iwanaga Y, Nakai M, et al. Combination of coronary CT angiography, FFR(CT) , and risk factors in the prediction of major adverse cardiovascular events in patients suspected CAD. Clin Cardiol 2023; 46: 494-501.
  49. Yang S, Chung J, Lesina K, et al. Long-term prognostic implications of CT angiography-derived fractional flow reserve: results from the DISCOVER-FLOW study. J Cardiovasc Comput Tomogr 2024; 18: 251-8.
  50. Hong D, Dai N, Lee SH, et al. Fractional flow reserve and fractional flow reserve gradient from CCTA for predicting future coronary events. JACC Asia 2024; 4: 735-47.
  51. Li Z, Xu T, Wang Z, et al. Prognostic significance of computed tomography-derived fractional flow reserve for long-term outcomes in individuals with coronary artery disease. J Am Heart Assoc 2025; 14: e037988.
  52. Yang J, Shan D, Wang X, et al. On-site computed tomography-derived fractional flow reserve to guide management of patients with stable coronary artery disease: the TARGET randomized trial. Circulation 2023; 147: 1369-81.
  53. Di Pietro G, Improta R, De Filippo O, et al. Clinical impact of CCT-FFR as first-strategy in patients with symptomatic stable coronary artery disease: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr 2025; 19: 174-82.
  54. Hamilton-Craig C, Ugander M, Greenwood JP, Kozor R. Stress perfusion cardiovascular magnetic resonance imaging: a guide for the general cardiologist. Heart 2023; 109: 428-33.
  55. Patel AR, Salerno M, Kwong RY, et al. Stress cardiac magnetic resonance myocardial perfusion imaging: JACC review topic of the week. J Am Coll Cardiol 2021; 78: 1655-68.
  56. Bazoukis G, Papadatos SS, Michelongona A, et al. Contemporary role of cardiac magnetic resonance in the management of patients with suspected or known coronary artery disease. Medicina 2021; 57: 649.
  57. Silva T, Pezel T, Jerosch-Herold M, Coelho-Filho OR. The role and advantages of cardiac magnetic resonance in the diagnosis of myocardial ischemia. J Thorac Imaging 2023; 38: 235-46.
  58. Pezel T, Hovasse T, Lefèvre T, et al. Prognostic value of stress CMR in symptomatic patients with coronary stenosis on CCTA. JACC Cardiovasc Imaging 2022; 15: 1408-22.
  59. Ricci F, Khanji MY, Bisaccia G, et al. Diagnostic and prognostic value of stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease: a systematic review and meta-analysis. JAMA Cardiol 2023; 8: 662-73.
  60. Zhou W, Lee JCY, Leung ST, et al. Long-term prognosis of patients with coronary microvascular disease using stress perfusion cardiac magnetic resonance. JACC Cardiovasc Imaging 2021; 14: 602-11.
  61. Danad I, Raijmakers PG, Driessen RS, et al. Comparison of coronary CT angiography, SPECT, PET, and hybrid imaging for diagnosis of ischemic heart disease determined by fractional flow reserve. JAMA Cardiol 2017; 2: 1100-7.
  62. Patel KK, Al Badarin F, Chan PS, et al. Randomized comparison of clinical effectiveness of pharmacologic SPECT and PET MPI in symptomatic CAD patients. JACC Cardiovasc Imaging 2019; 12: 1821-31.
  63. Naya M, Murthy VL, Taqueti VR, et al. Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography. J Nucl Med 2014; 55: 248-55.
  64. Ruddy TD, Tavoosi A, Taqueti VR. Role of nuclear cardiology in diagnosis and risk stratification of coronary microvascular disease. J Nucl Cardiol 2023; 30: 1327-40.
  65. Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 2017; 135: 1075-92.
  66. Doris MK, Meah MN, Moss AJ, et al. Coronary (18)F-Fluoride uptake and progression of coronary artery calcification. Circ Cardiovasc Imaging 2020; 13: e011438.
  67. Berman DS, Kang X, Slomka PJ, et al. Underestimation of extent of ischemia by gated SPECT myocardial perfusion imaging in patients with left main coronary artery disease. J Nucl Cardiol 2007; 14: 521-8.
  68. Nkoulou R, Fuchs TA, Pazhenkottil AP, et al. Absolute myocardial blood flow and flow reserve assessed by gated SPECT with cadmium-zinc-telluride detectors using 99mTc-tetrofosmin: head-to-head comparison with 13N-ammonia PET. J Nucl Med 2016; 57: 1887-92.
  69. Agostini D, Roule V, Nganoa C, et al. First validation of myocardial flow reserve assessed by dynamic (99m)Tc-sestamibi CZT-SPECT camera: head to head comparison with (15)O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging 2018; 45: 1079-90.
  70. Cantoni V, Green R, Acampa W, et al. Diagnostic performance of myocardial perfusion imaging with conventional and CZT single-photon emission computed tomography in detecting coronary artery disease: a meta-analysis. J Nucl Cardiol 2021; 28: 698-715.
  71. Assante R, Zampella E, Cantoni V, et al. Prognostic value of myocardial perfusion imaging by cadmium zinc telluride single-photon emission computed tomography in patients with suspected or known coronary artery disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2023; 50: 3647-58.
  72. Stillman AE, Gatsonis C, Lima JAC, et al. Coronary computed tomography angiography compared with single photon emission computed tomography myocardial perfusion imaging as a guide to optimal medical therapy in patients presenting with stable angina: the RESCUE Trial. J Am Heart Assoc 2020; 9: e017993.
  73. Lee SP, Seo JK, Hwang IC, et al. Coronary computed tomography angiography vs. myocardial single photon emission computed tomography in patients with intermediate risk chest pain: a randomized clinical trial for cost-effectiveness comparison based on real-world cost. Eur Heart J Cardiovasc Imaging 2019; 20: 417-25.
  74. Zhang RS, Weber BN, Araiza-Garaygordobil D, Garshick MS. Colchicine for the prevention of cardiovascular disease: potential global implementation. Curr Cardiol Rep 2024; 26: 423-34.
  75. Everett BM, MacFadyen JG, Thuren T, et al. Inhibition of Interleukin-1b and reduction in atherothrombotic cardiovascular events in the CANTOS Trial. J Am Coll Cardiol 2020; 76: 1660-70.
  76. Ridker PM, Baeres FMM, Hveplund A, et al. Rationale, design, and baseline clinical characteristics of the ziltivekimab cardiovascular outcomes trial: interleukin-6 inhibition and atherosclerotic event rate reduction. JAMA Cardiol 2026; 11: 89-97.
  77. Langseth MS, Opstad TB, Bratseth V, et al. Markers of neutrophil extracellular traps are associated with adverse clinical outcome in stable coronary artery disease. Eur J Prev Cardiol 2018; 25: 762-9.
  78. Szymańska Z, Staniewski A, Karpiński M, et al. The role of neutrophil extracellular networks in cardiovascular pathology. Cells 2025; 14: 1562.
  79. Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013; 33: 2032-40.
  80. Hayden H, Ibrahim N, Klopf J, et al. ELISA detection of MPO-DNA complexes in human plasma is error-prone and yields limited information on neutrophil extracellular traps formed in vivo. PLoS One 2021; 16: e0250265.
  81. Baaten C, Nagy M, Spronk HMH, et al. NETosis in cardiovascular disease: an opportunity for personalized antithrombotic treatments? Arterioscler Thromb Vasc Biol 2024; 44: 2366-70.
  82. Byun YS, Lee JH, Arsenault BJ, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 2015; 65: 1286-95.
  83. Gilliland TC, Liu Y, Mohebi R, et al. Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes. J Am Coll Cardiol 2023; 81: 1780-92.
  84. Patel RS, Ghasemzadeh N, Eapen DJ, et al. Novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. Circulation 2016; 133: 361-9.
  85. Hirata Y, Yamamoto E, Tokitsu T, et al. Reactive oxygen metabolites are closely associated with the diagnosis and prognosis of coronary artery disease. J Am Heart Assoc 2015; 4: e001451.
  86. Hiraya D, Sato A, Hoshi T, et al. Additional effect of coronary high-intensity plaque on T1-weighted magnetic resonance imaging with circulating malondialdehyde-modified low-density lipoprotein on cardiac events. Circ J 2021; 85: 2032-9.
  87. Mróz K, Paszek E, Baran M, et al. Elevated carbonylated proteins are associated with major cardiovascular events in patients with chronic coronary syndrome: a cohort study. Kardiol Pol 2024; 82: 708-15.
  88. Mohammed BM, Matafonov A, Ivanov I, et al. An update on factor XI structure and function. Thromb Res 2018; 161: 94-105.
  89. Moellmer SA, Puy C, McCarty OJT. Biology of factor XI. Blood 2024; 143: 1445-54.
  90. Paszek E, Pociask E, Ząbczyk M, et al. Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients. Atherosclerosis 2022; 346: 124-32.
  91. Chen H, Shen M, Niu R, et al. Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: a nested case-control study. J Thromb Haemost 2021; 19: 2781-90.
  92. Rao SV, Kirsch B, Bhatt DL, et al. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor xia inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 2022; 146: 1196-206.
  93. Gibson CM, Bahit MC, Mehran R, et al. Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: rationale and design of the phase 3 (Librexia ACS). Am Heart J 2025; 285: 21-8.
  94. Karakas M, Schulte C, Appelbaum S, et al. Circulating micro­RNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study. Eur Heart J 2017; 38: 516-23.
  95. Pedersen OB, Grove EL, Nissen PH, et al. Expression of microRNA predicts cardiovascular events in patients with stable coronary artery disease. Thromb Haemost 2023; 123: 307-16.
  96. Hortmann M, Walter JE, Benning L, et al. Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery disease. Int J Cardiol 2019; 275: 129-35.
  97. Gasecka A, Błażejowska E, Pluta K, et al. Ticagrelor downregulates the expression of proatherogenic and proinflammatory miR125-b compared to clopidogrel: a randomized, controlled trial. Int J Cardiol 2024; 406: 132073.
  98. Arbab-Zadeh A, Fuster V. From detecting the vulnerable plaque to managing the vulnerable patient: JACC state-of-the-art review. J Am Coll Cardiol 2019; 74: 1582-93.
  99. Rehan R, Yong A, Ng M, et al. Coronary microvascular dysfunction: a review of recent progress and clinical implications. Front Cardiovasc Med 2023; 10: 1111721.
  100. Bosco E, Hsueh L, McConeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021; 21: 241.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications